Agios Pharmaceuticals (NASDAQ:AGIO) insider Christopher Bowden sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, April 12th. The stock was sold at an average price of $85.10, for a total transaction of $170,200.00. Following the transaction, the insider now owns 2,881 shares in the company, valued at $245,173.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Christopher Bowden also recently made the following trade(s):
- On Friday, February 16th, Christopher Bowden sold 2,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $77.65, for a total transaction of $155,300.00.
- On Thursday, February 1st, Christopher Bowden sold 2,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $78.75, for a total transaction of $157,500.00.
Shares of NASDAQ AGIO opened at $86.86 on Wednesday. Agios Pharmaceuticals has a fifty-two week low of $45.11 and a fifty-two week high of $89.33. The company has a market capitalization of $5,006.34, a P/E ratio of -12.87 and a beta of 1.98.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.65) by ($0.16). Agios Pharmaceuticals had a negative net margin of 731.60% and a negative return on equity of 76.67%. The business had revenue of $9.80 million during the quarter, compared to analyst estimates of $12.65 million. During the same quarter in the prior year, the company earned ($1.34) earnings per share. The company’s quarterly revenue was down 56.7% on a year-over-year basis. equities analysts predict that Agios Pharmaceuticals will post -6.25 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Agios Pharmaceuticals by 41.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,600 shares of the biopharmaceutical company’s stock valued at $149,000 after buying an additional 762 shares during the period. State of Alaska Department of Revenue acquired a new position in Agios Pharmaceuticals in the fourth quarter valued at approximately $160,000. Bank of Montreal Can lifted its holdings in Agios Pharmaceuticals by 74.8% in the fourth quarter. Bank of Montreal Can now owns 3,551 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 1,520 shares during the period. Macquarie Group Ltd. acquired a new position in Agios Pharmaceuticals in the third quarter valued at approximately $245,000. Finally, Xact Kapitalforvaltning AB acquired a new position in Agios Pharmaceuticals in the fourth quarter valued at approximately $259,000. Institutional investors and hedge funds own 82.41% of the company’s stock.
AGIO has been the topic of a number of research reports. Oppenheimer set a $83.00 target price on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, December 26th. Needham & Company LLC upped their target price on shares of Agios Pharmaceuticals from $72.00 to $86.00 and gave the stock a “buy” rating in a research report on Thursday, February 15th. BidaskClub upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, January 16th. Zacks Investment Research upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $84.00 target price on the stock in a research report on Tuesday, January 16th. Finally, SunTrust Banks reiterated a “buy” rating and set a $101.00 target price (up from $80.00) on shares of Agios Pharmaceuticals in a research report on Thursday, February 15th. Four equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $87.00.
COPYRIGHT VIOLATION WARNING: “Christopher Bowden Sells 2,000 Shares of Agios Pharmaceuticals (AGIO) Stock” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/18/christopher-bowden-sells-2000-shares-of-agios-pharmaceuticals-agio-stock.html.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.